600276 恒瑞醫藥
按盤價 
48.070 +0.140 (+0.292%) | 2026/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2025/12 人民幣(K¥) | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | ||
| 營業總收入 | 24,408,763 | 5.26% | 31,629,416 | 27,984,605 | 22,819,785 | 21,275,271 | |
| 減：營業總成本 | 17,294,496 | 2.24% | 23,093,098 | 21,008,001 | 18,214,153 | 17,747,084 | |
| 其中:營業成本 | 3,225,793 | 0.95% | 4,362,656 | 3,848,177 | 3,525,248 | 3,486,639 | |
| 財務費用 | (116,288) | -65.09% | (406,945) | (572,732) | (478,390) | (470,867) | |
| 資產減值損失 | (88,695) | 552.20% | (86,914) | (32,538) | (107,217) | (146,684) | |
| 公允價值變動收益 | 803,620 | 721.69% | 173,574 | 108,631 | (58,257) | 76,503 | |
| 投資收益 | (107,830) | 164.14% | (80,185) | 4,279 | (49,157) | 387,365 | |
| 其中：對聯營企業和合營企業的投資收益 | (133,695) | 140.89% | (97,143) | (21,581) | (72,696) | (62,996) | |
| 營業利潤 | 7,993,894 | 20.67% | 8,990,003 | 7,490,632 | 4,909,905 | 4,111,960 | |
| 利潤總額 | 7,728,630 | 20.53% | 8,707,626 | 7,169,690 | 4,667,110 | 3,968,492 | |
| 減：所得稅費用 | 805,476 | 23.58% | 990,623 | 832,695 | 389,289 | 153,351 | |
| 淨利潤 | 6,923,154 | 20.19% | 7,717,002 | 6,336,995 | 4,277,821 | 3,815,142 | |
| 減：非控股權益 | (250) | -102.76% | 5,947 | 468 | (24,615) | (91,233) | |
| 股東淨利潤 | 6,923,404 | 20.38% | 7,711,055 | 6,336,527 | 4,302,436 | 3,906,375 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 1.050 | 17.98% | 1.190 | 1.000 | 0.680 | 0.610 | |
| 每股派息 (元) * | -- | -- | 0.200 | 0.200 | 0.200 | 0.160 | |
| 每股淨資產 (元) * | 10.067 | 12.29% | 9.232 | 7.136 | 6.344 | 5.929 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 13/11/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
